Skip to main content
Equibles

CITADEL ADVISORS LLC

Position in SABS — SAB Biotherapeutics, Inc.

CIK 1423053 MIAMI, FL
Back to SABS Full portfolio

Position in SABS

as of Jun 30, 2026 · filed Sep 2, 2026
Position Value
$244,908
+$244,908 QoQ
Shares Held
62,797
Ownership
0.069%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2021
15 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in SABS Over Time

Shares Held

Position Value (USD)

Derivatives in SABS

reported options exposure · as of Jun 30, 2026
CallValue
$315,900
CallShares
81,000
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

CITADEL ADVISORS LLC holds $6,151,065,112 across 436 Biotechnology names. SABS ranks #303 (0.0% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 ONC
BeOne Medicines Ltd.
 1,425,517 $406,229,578
2 BBIO
BridgeBio Pharma, Inc.
 3,760,028 $280,046,885
3 INSM
INSMED Inc
 2,556,973 $272,624,460
4 MDGL
Madrigal Pharmaceuticals, Inc.
 507,233 $272,358,759
5 VRTX
Vertex Pharmaceuticals Inc / Ma
 510,430 $253,545,893
6 JAZZ
Jazz Pharmaceuticals plc
 1,006,676 $242,578,715
7 MANE
Veradermics, Inc
 1,877,775 $230,853,658
8 ROIV
Roivant Sciences Ltd.
 5,576,261 $197,343,876

All Filings in SABS

Export CSV
12 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $315,900 81,000
2026-06-30 $244,908 62,797
2026-03-31 $102,261 26,700
2026-03-31 $164,307 42,900
2025-12-31 $66,011 17,650
2025-06-30 $30,001 17,095
2024-09-30 $27,823 10,305
2023-12-31 $11,502 16,719
2023-03-31 $12,496 28,400
2022-12-31 $64,436 109,215
2022-09-30 $28,153 40,162
2021-12-31 $189,236 24,230